Details of the Drug Combination

General Information of Drug Combination (ID: DCGB4W8)

• Drug Combination Name: Arfolitixorin + BHV-0223
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Arfolitixorin (DMIXMYK): Small molecular drug
  BHV-0223 (DMBLM5H): N.A.
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 5.86
  Bliss Independence Score: 5.86
  Loewe Additivity Score: 7.82
  LHighest Single Agent (HSA) Score: 7.84

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
• [2] ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)